Mozart Therapeutics

Seattle, Washington, USA

Mozart Therapeutics develops therapies for celiac disease and other immune-related conditions.

Facts

HQ
Seattle, Washington, USA
Sectors
Biotechnology, Biopharma, Immunology
Founded
2023
Type
Corporation Seattle business license
Registered name
Mozart Therapeutics Inc Seattle business license
Stage
Series C

Is this your organization? Claim it

Juno Therapeutics’ 2013 launch spurred Seattle cell-therapy boom after $300M+ raise and $9B+ 2018 sale to Celgene

Juno Therapeutics, founded in 2013, accelerated cell therapy development by raising over $300 million, going public within a year, and selling to Celgene for more than $9 billion in 2018, and its alumni spawned many Seattle-area biotech startups. The company’s success attracted capital, validated Seattle as a cellular and gene therapy hub, and influenced the region’s biotech entrepreneurship and leadership.

See all 7 stories, episodes and videos about Mozart Therapeutics.

People

  • Katie Fanning Executive, President and Chief Executive Officer